Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Options Strategies & the Zacks Rank
- PFP 5/21: Below the Surface
- AWS 5/20: The Fed In Focus This Week
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/20/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
| EAGLE BULK S | EGLE | 7.84% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Luminex Corporation ( LMNX - Analyst Report ) recently revealed that it won clearance from the FDA for its xTAG Gastrointestinal Pathogen Panel, which is a complete molecule-based diagnostic assay. It tests for over 90% of parasitic, bacterial and viral reasons for gastroenteritis in one assay. The xTAG Gastrointestinal Pathogen Panel has been commercialized in the U.S. It is believed that its use will permit better detection of pathogens.
The xTAG Gastrointestinal Pathogen Panel is a complete multiplexed offering. The assay concurrently tests for as many as eleven of the most frequently occurring causes of gastroenteritis. The xTAG Gastrointestinal Pathogen Panel is able to provide outcomes in less than five hours. The assay is meant for the Luminex 100/200 system.
Earlier, Luminex accomplished the takeover of U.S.-based diagnostic testing company, GenturaDx on July 11, 2012. The GenturaDx deal is in line with Luminex’s strategy of pursuing acquisitions to drive growth. Its technology when combined with Luminex’s MultiCode chemistry will enable the company to develop user-friendly advanced products for its customers.
Luminex possesses an extensive product portfolio and a strong pipeline of novel assays, which are expected to support growth going ahead. The company is awaiting FDA approval for its NeoPlex4 assays to drive future growth. It may benefit from its latest acquisitions if it maintains integration synergies.
However, Luminex operates in a highly competitive life sciences industry. The company competes with Affymetrix ( AFFX - Analyst Report ) , Life Technologies Corporation ( LIFE - Analyst Report ) and Sequenom ( SQNM - Snapshot Report ) , among others. Moreover, sluggish growth in its core markets as well as the ongoing European austerity measures are challenges faced by Luminex. We are currently Neutral on the stock, which carries a short-term rating of Zacks Rank #3 (Hold).
Read the full Analyst Report on LIFE
Read the full Analyst Report on LMNX
Read the full Analyst Report on AFFX
Read the full Snapshot Report on SQNM